# Effect of Hydralazine on Alzheimer's Disease

> **NCT04842552** · PHASE3 · UNKNOWN · sponsor: **Shahid Sadoughi University of Medical Sciences and Health Services** · enrollment: 424 (estimated)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Hydralazine hydrochloride 25mg tablets
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04842552
- **Lead sponsor:** Shahid Sadoughi University of Medical Sciences and Health Services
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-02
- **Primary completion:** 2023-06-01
- **Final completion:** 2023-12-20
- **Target enrollment:** 424 (ESTIMATED)
- **Last updated:** 2022-01-06

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04842552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04842552, "Effect of Hydralazine on Alzheimer's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04842552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*